[ad_1]
Newton, Massachusetts, December 1, 2021 /PRNewswire/–Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering a new type of cancer therapy, today announced that Karyopharm’s Board of Directors Compensation Committee has granted stock options to purchase a total of 68,900 Karyopharm common shares from 13 new employees. The grant date is November 30, 2021. According to Nasdaq Listing Rule 5635(c)(4), stock options are granted as an important incentive for new employees to work at Karyopharm.
The exercise price of each stock option is $6.95 per share, which is the closing price of Karyopharm’s common stock on November 30, 2021. The exercise time of each stock option is four years, of which 25% of the total number of shares related to the stock option is exercised on the first anniversary of the employment start date of the applicable employee and 1/48 of the total number of shares…
The full story can be found on Benzinga.com
[ad_2]
Source link
